Compare · CAH vs HKPD
CAH vs HKPD
Side-by-side comparison of Cardinal Health Inc. (CAH) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CAH is the larger of the two at $65.61B, about 16525.8x HKPD ($4.0M).
- CAH has been more active in the news (17 items in the past 4 weeks vs 3 for HKPD).
- CAH has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cardinal Health Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- -
- -
- Market cap
- $65.61B
- $4.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 17
- 3
- Recent ratings
- 25
- 0
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Latest CAH
- Director Hall Patricia Hemingway was granted 1,204 shares, increasing direct ownership by 4% to 29,849 units (SEC Form 4)
- Director Johri Akhil was granted 1 shares, increasing direct ownership by 0.00% to 22,869 units (SEC Form 4)
- Director Killefer Nancy was granted 755 shares, increasing direct ownership by 3% to 28,379 units (SEC Form 4)
- Director Mundkur Christine was granted 755 shares, increasing direct ownership by 10% to 8,291 units (SEC Form 4)
- Director Musslewhite Robert W was granted 755 shares, increasing direct ownership by 36% to 2,871 units (SEC Form 4)
- Director Ramakrishna Sudhakar was granted 755 shares, increasing direct ownership by 36% to 2,871 units (SEC Form 4)
- Director Edison Sheri H. was granted 755 shares, increasing direct ownership by 5% to 15,603 units (SEC Form 4)
- New insider Zielinski Anita A claimed ownership of 5,715 shares (SEC Form 3)
- Director Evans David C was granted 755 shares, increasing direct ownership by 5% to 16,128 units (SEC Form 4)
- Director Brennan Michelle was granted 755 shares, increasing direct ownership by 9% to 8,841 units (SEC Form 4)
Latest HKPD
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form S-8 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 20-F filed by Cellyan Biotechnology Co. Ltd